Replies to post #392440 on Innovation Pharmaceuticals Inc (IPIX)

[StockJumper25]

Thumbs-Up Steele, agreed on the forth-coming announcement (hopefully) for B-OM.

What is astonishingly absurd is why we don't hear about more research finds like the below, that hopefully the NIH is taking seriously.

https://europepmc.org/article/med/35695877 -- This updated June 2022 this year.

Brilacidin (PMX-30063), a non-peptide defensin-mimetic small molecule, inhibits SARS-CoV-2 viral infection but the anti-viral mechanism is not defined. Here we determined its effect on the specific step of the viral life cycle. Brilacidin blocked SARS-CoV-2 infection but had no effect after viral entry. Brilacidin inhibited pseudotyped SARS-CoV-2 viruses expressing spike proteins from the P.1 Brazil strain and the B.1.1.7 UK strain. Brilacidin affected viral attachment in hACE2-dependent and independent manners depending on the concentrations. The inhibitory effect on viral entry was not mediated through blocking the binding of either the spike receptor-binding domain or the spike S1 protein to hACE2 proteins. Taken together, brilacidin inhibits SARS-CoV-2 infection by blocking viral entry and is active against SARS-CoV-2 variants.

Absolutely criminal that this can be overlooked as it stands now.